SutentŪ Gains FDA Approval to Treat Pancreatic Neuroendocrine Tumors

Saturday, May 21, 2011 General News
Email Print This Page Comment bookmark
Font : A-A+

MANHATTAN BEACH, Calif., May 20, 2011 The Pfizer drug SutentŪ (sunitinib) has been approved for the treatment of advanced pancreatic neuroendocrine tumors by the U.S. Food and Drug Administration (FDA). SutentŪ is the second targeted drug to be approved this month for the treatment of pancreatic neuroendocrine tumors, which make up less than five percent of all pancreatic cancer diagnoses and are generally slower growing and less aggressive than the more common form of pancreatic cancer, pancreatic adenocarcinoma.


"The FDA approval today of SutentŪ, and AfinitorŪ just two weeks ago, is a significant step forward for patients with pancreatic neuroendocrine tumors. Treatment options for pancreatic neuroendocrine tumors have not been well-established, so the news of two new drugs approved by the FDA is exciting," stated Julie Fleshman, President and CEO of the Pancreatic Cancer Action Network.

In order to gain approval, SutentŪ underwent clinical trials in the U.S. and several other countries to show that the drug was effective and safe for patients with pancreatic neuroendocrine tumors. SutentŪ had previously been approved for the treatment of other cancer types, but needed to be tested specifically in patients with pancreatic neuroendocrine tumors. The Oncologic Drug Advisory Council recommended that both SutentŪ and AfinitorŪ be approved for the treatment of pancreatic neuroendocrine tumors in mid-April, 2011. AfinitorŪ was approved by the FDA on May 5.

The Pancreatic Cancer Action Network encourages all patients to consider clinical trials when exploring treatment options. For more information about ongoing clinical trials or other questions about pancreatic cancer diagnosis and treatment, or to learn more about pancreatic neuroendocrine tumors and the Pancreatic Cancer Action Network, visit

About the Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization is leading the way to increase the survival rate for people diagnosed with this devastating disease through a bold initiative--The Vision of Progress: Double the Pancreatic Cancer Survival Rate by 2020. Together, we can know, fight and end pancreatic cancer by intensifying our efforts to heighten awareness, raise funds for comprehensive private research, and advocate for dedicated federal research to advance early diagnostics, better treatments and increase chances of survival.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Julie Fleshman

SOURCE Pancreatic Cancer Action Network

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store